{"id":"W4379336470","doi":"10.1200/jco.2023.41.16_suppl.4511","title":"Fibroblast growth factor receptor 3 (<i>FGFR3</i>) alterations in PROOF 302: A phase III trial of infigratinib (BGJ398) as adjuvant therapy in patients (pts) with invasive urothelial carcinoma (UC).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Tolerability; Internal medicine; Placebo; Oncology; Metastatic Urothelial Carcinoma; Adjuvant therapy; Cancer; Randomized controlled trial; Surgery; Adverse effect; Bladder cancer; Urothelial carcinoma; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000769562,0.001096151,0.00158485,0.0002194753,0.0002103519,0.0008466154,0.0006504494,0.0008552236,0.005184351],"category_scores_gemma":[0.0006265706,0.0004522723,0.001306148,0.0002534672,0.0005460753,0.000671665,0.0003475734,0.002242986,0.0009467094],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000662777,"about_ca_system_score_gemma":0.001190565,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001014627,"about_ca_topic_score_gemma":0.003323639,"domain_scores_codex":[0.9998211,0.00006969305,0.00001163643,0.00003922295,0.00001766701,0.00004068615],"domain_scores_gemma":[0.9997558,0.0000341259,0.00005519874,0.00001542882,0.0000213508,0.0001181277],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8642492,0.01526238,0.001698218,0.003002518,0.001758755,0.0001884459,0.0001903727,0.001731787,0.03584325,0.0005391135,0.005584973,0.06995104],"study_design_scores_gemma":[0.8374535,0.1518684,0.003371671,0.0001032633,0.0007191082,0.0003017589,0.00005459072,0.0007736204,0.002314447,0.0003552571,0.002654573,0.00002973761],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9799385,0.007845651,0.0006856791,0.0008938247,0.0003247022,0.003970293,0.00192017,0.0002786685,0.004142515],"genre_scores_gemma":[0.9850307,0.004311204,0.001366821,0.001179377,0.00009023077,0.002255602,0.002218051,0.00003615778,0.00351198],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005184351,"threshold_uncertainty_score":0.0173434,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08624236105440229,"score_gpt":0.4171832021538532,"score_spread":0.3309408410994509,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}